A Sequential Predictive Power Design for a COVID Vaccine Trial

References

• Amrhein, V., Greenland, S., and McShane, B. (2019), “Scientists Rise Up Against Statistical Significance,” Nature 567, 305–307.
   PubMed Web of Science ®Google Scholar
• Baden, L. R., et al. (2021), “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,” New England Journal of Medicine, 384, 403–416.
   PubMed Web of Science ®Google Scholar
• Dmitrienko, A., and Wang, M. D. (2006), “Bayesian Predictive Approach to Interim Monitoring in Clinical Trials,” Statistics in Medicine, 25, 2178–2195.
   PubMed Web of Science ®Google Scholar
• Evans, M., and Moshonov, H. (2006), “Checking for Prior-Data Conflict,” Bayesian Analysis, 1, 893–914.
   Web of Science ®Google Scholar
• Food and Drug Administration (FDA), (2020), “Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry,” available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-andlicensure-vaccines-prevent-covid-19.
   Google Scholar
• Gordon Lan, K. K., and DeMets, D. L. (1983), “Discrete Sequential Boundaries for Clinical Trials,” Biometrika, 70, 659–663.
   Web of Science ®Google Scholar
• Gsponer, T., Gerber, F., Bornkamp, B., Ohlssen, D., Vandemeule- broecke, M., and Schmidli, H. (2014), “A Practical Guide to Bayesian Group Sequential Designs,” Pharmaceutical Statistics, 13, 71–80.
   PubMed Web of Science ®Google Scholar
• Harhay, M. O., and Donaldson, G. C. (2020), “Guidance on Statistical Reporting to Help Improve Your Chances of a Favorable Statistical Review,” in American Journal of Respiratory and Critical Care Medicine, 201, 1035–1038.
   PubMed Web of Science ®Google Scholar
• Mehta, C., and Tsiatis, A. (2001), “Flexible Sample Size Considerations Using Information-Based Interim Monitoring,” Drug Information Journal - Drug Information Portal 35, 1095–1112.
   Web of Science ®Google Scholar
• Netea, M. G., Giamarellos-Bourboulis, E. J., Domínguez-Andrés, J., Curtis, N., Crevel, R. van, Veerdonk, F. L. van de, and Bonten, M. (2020), “Trained Immunity: A Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection,” Cell 181, 969–977.
   PubMed Web of Science ®Google Scholar
• O’Neill, L. A. J., and Netea, M. G. (2020), “BCG-Induced Trained Immunity: Can It Offer Protection Against COVID-19?” Nature Reviews Immunology, 20, 335–337.
   PubMed Web of Science ®Google Scholar
• Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R.,? ahin, U., Jansen, K. U., Gruber, W. C., Aberg, J., Addo, M., Akhan, S., Albertson, T., Al-Ibrahim, M., Alt?n, S., Anderson, C., Andrews, C., Arora, S., Balik, I., Barnett, E., Bauer, G., Baumann-Noss, S., Berhe, M., Bradley, P., Brandon, D., Brune, D., Burgher, A., Butcher, B., Butuk, D., Cannon, K., Cardona, J., Cavelli, R., Chalhoub, F., Christensen, S., Christensen, T., Chu, L., Cox, S., Crook, G., Davis, M., Davit, R., Denham, D., Dever, M., Donskey, C., Doust, M., Dunn, M., Earl, J., Eder, F., Eich, A., Ensz, D., Essink, B., Falcone, R., Falsey, A., Farrington, C., Finberg, R., Finn, D., Fitz-Patrick, D., Fortmann, S., Fouche, L., Fragoso, V., Frenck, R., Fried, D., Fuller, G., Fussell, S., Garcia-Diaz, J., Gentry, A., Glover, R., Greenbaum, C., Grubb, S., Hammitt, L., Harper, C., Harper, W., Hartman, A., Heller, R., Hendrix, E., Herrington, D., Jennings, T., Karabay, O., Kaster, S., Katzman, S., Kingsley, J., Klein, N., Klein, T., Koch, M., Köksal, I., Koren, M., Kutner, M., Lee, M., Leibowitz, M., Levin, M., Libster, R., Lillestol, M., Lucasti, C., Luttermann, M., Manning, M. B. E., Martin, M., Matherne, P., McMurray, J., Mert, A., Middleton, R., Mitha, E., Morawski, E., Moreira, E., Mulligan, M., Murray, A., Mussaji, M., Musungaie, D., Nell, H., Odekirk, L., Ogbuagu, O., Paolino, K., Patel, S., Peterson, J., Pickrell, P., Polack, F., Poretz, D., Raad, G., Randall, W., Rankin, B., Reynolds, Riesenberg, R., Rodriguez, H., Rosen, J., Rubino, J., Rupp, R., Saiger, S., Salata, R., Saleh, J., Schaefer, A., Schear, M., Schultz, A., Schwartz, H., Segall, N., Seger, W., Senders, S., Sharp, S., Shoffner, S., Simsek Yavuz, S., Sligh, T., Smith, W., Stacey, H., Stephens, M., Studdard, H., Tabak, F., Talaat, K., Thomas, S., Towner, W., Tran, V., Ünal, S., Usdan, L., Vanchiere, J., Varano, S., Wadsworth, E. T. L., Walsh, W., Walter, E., Wappner, D., Whiles, R., Williams, H., Wilson, J., Winkle, P., Winokur, P., Wolf, T., Yozviak, J., Zerbini, C. (2020), “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” New England Journal of Medicine, 383, 2603–2615.
   PubMed Web of Science ®Google Scholar
• Psioda, M. A., and Ibrahim, J. G. (2019), “Bayesian Clinical Trial Design Using Historical Data That Inform the Treatment Effect,” Biostatistics 20, 400–415.
   PubMed Web of Science ®Google Scholar
• Saville, B. R., Connor, J. T., Ayers, G. D., and Alvarez, J. (2014), “The Utility of Bayesian Predictive Probabilities for Interim Monitoring of Clinical Trials,” Clinical Trials, 11, 485–493.
   PubMed Web of Science ®Google Scholar
• Singh, S., Maurya, R. P., and Singh, R. K. (2020), “Trained Immunity” From Mycobacterium spp. Exposure or BCG Vaccination and COVID-19 Outcomes,” PLoS Pathog 16, e1008969.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Abrams, K. R., and Myles, J. P. (2004), Bayesian Approaches to Clinical Trials and Health-Care Evaluation, Chichester: Wiley. Available at: https://cds.cern.ch/record/997022.
   Google Scholar
• Walker, L. E., and Nieto-Barajas, S. G. (2002), “Markov Beta and Gamma Processes for Modelling Hazard Rates,” Scandinavian Journal of Statistics, 29, 413–424.
   Web of Science ®Google Scholar
• Wang, H., Rosner, G. L., and Goodman, S. N. (2016), “Quantifying Over-Estimation in Early Stopped Clinical Trials and the “Freezing Effect” on Subsequent Research” Clinical Trials, 13, 621–631.
   PubMed Web of Science ®Google Scholar
• Wasserstein, R. L., Schirm, A. L., and Lazar, N. A. (2019), “Moving to a World Beyond ‘p < 0.05’,” The American Statistician 73, 1–19.
   Web of Science ®Google Scholar
• Woodcock, J., and LaVange, L. M. (2017), “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both,” New England Journal of Medicine, 1, 62–70.
   Google Scholar
• Zhu, H., and Yu, Q. (2017), “A Bayesian Sequential Design Using Alpha Spending Function to Control Type I Error,” Statistical Methods in Medical Research, 26, 2184–2196.
   PubMed Web of Science ®Google Scholar